From reactive to predictive: Concerto ’s new compositions

In his 2016 book Healthcare Disrupted, Dr Jeff Elton sketched out how healthcare would move from being reactive to proactive thanks to the ubiquity of electronic health records (EHRs) and other datasets.   That future is now upon us, says Elton, CEO of precision oncology business Concerto HealthAI. whose mission is to combine RWE and AI to drive better insights and patient outcomes. The firm, which recently raised $150m to invest in growing ‘next-generation’ clinical research, is now busy putting technologies and tools into hundreds of life science companies and clinical settings to ask questions of real-world data retrospectively and prospectively.  The insights flowing from this near real-time clinical data have great potential to accelerate meaningful clinical innovations, complementing the more traditional and slower approaches. “We believe that research and the conduct of care, are integrally linked,” says Elton. “And we believe that faster cycles of research questions being asked leads to faster cycles, where the insights from those can be put into practice. “Instead of doing surrogate measures, we ' re very big believers in having direct clinical measures. You can do things now with the tools in a fraction of the time that you would have done before, they will increase in utility much more rapidly. It is a frontier where we will see tremendous progress. Regulatory approvals are getting faster too, thanks to the application of RWD components, says Elto...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news